Full-Time
Posted on 1/25/2025
Develops and sells probiotic products online
$170k - $200kAnnually
Expert
Remote in USA
This position is US-based and 100% remote.
You match the following Seed Health's candidate preferences
Employers are more likely to interview you if you match these preferences:
Seed Health focuses on developing and selling consumer products that utilize the benefits of microbes to enhance both human and planetary health. The company offers a range of scientifically-backed probiotics for humans and pets through its e-commerce platform, targeting health-conscious consumers interested in microbiome-related products. What sets Seed Health apart from its competitors is its strong emphasis on rigorous scientific research and innovation, ensuring that all products are effective and safe. Additionally, Seed Health engages in educational initiatives to promote awareness about microbial health, using creative marketing strategies to make complex scientific concepts more accessible to the public. The company's goal is to improve overall well-being by leveraging the power of microbes.
Company Size
201-500
Company Stage
Series A
Total Funding
$38.9M
Headquarters
Los Angeles, California
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Company Match
Mental Health Support
Wellness Program
Remote Work Options
(In fact, one of its editors previously covered the Daily Synbiotic at The Chalkboard Mag) But it wasn't until Seed Health launched its VS-01(TM) Vaginal Synbiotic that I decided to give the brand a try to rebalance my microbiome and the rest of my system.
The study, which is the first to show that a multi-strain vaginal synbiotic can establish a protective vaginal environment, will be presented at the Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology (IDSOG)The data demonstrate that VS-01™ successfully cultivates a vaginal microbiome dominated by Lactobacillus crispatus, reduces harmful microbes, and combats vaginal dysbiosisThese results underscore the potential of the vaginal microbiome and microbiome-directed innovations to redefine standards of care in women's healthBOSTON, Aug. 1, 2024 /PRNewswire/ -- Seed Health will present new clinical data on its flagship vaginal microbiome innovation, VS-01™ Vaginal Synbiotic, at the upcoming 2024 Infectious Diseases Society for Obstetrics and Gynecology (IDSOG) Annual Meeting. Data from a randomized, placebo-controlled clinical trial demonstrated the superior efficacy of VS-01™ in cultivating a stable and healthy vaginal microbiome. The synbiotic successfully established a protective environment dominated by Lactobacillus crispatus and inhibited harmful microbes associated with vaginal dysbiosis and inflammation. These findings highlight the transformative potential of proactive, preventive care centered on the vaginal microbiome, shifting the focus from traditional symptom management to maintaining a balanced and resilient vaginal ecology.A landmark 2012 study from vaginal microbiome researcher Jacques Ravel, Ph.D., demonstrated that the most stable and optimal vaginal microbiome is characterized by a dominance of the bacterium Lactobacillus crispatus, which plays a protective role in maintaining vaginal health. However, everyday factors such as menstruation, sexual activity, exercise, stress, contraceptives, and cleansers can deplete the abundance of L
LA-based probiotic company Seed is launching a new vaginal suppository that will help women maintain a more stable vaginal microbiome.
An optimal vaginal microbiome is a key driver of gynecological, urogenital, and reproductive healthVS-01™ is a multi-strain probiotic and prebiotic clinically validated to establish an optimal vaginal microbiome and sustain regulated vaginal pHBuilt on the research of renowned vaginal microbiome scientist Dr. Jacques Ravel, VS-01™ is the first to pioneer a microbial genomics approach powered by the most comprehensive host-microbiome vaginal data setLOS ANGELES, May 21, 2024 /PRNewswire/ -- Seed Health , a microbiome science company, today launched VS-01™ Vaginal Synbiotic, the first vaginal synbiotic clinically validated to rapidly establish an optimal vaginal microbiome dominated by Lactobacillus crispatus, the vagina's most protective bacteria. Dr. Jacques Ravel's pioneering research has elucidated the crucial role of the vaginal microbiome in gynecological, urogenital, and reproductive health, though everyday factors like stress, sex, menstruation, and diet can disrupt its equilibrium and deplete the abundance of L. crispatus. Dr
The company will present the results of two clinical trials that expand the potential health impact of its flagship 24-strain probiotic and prebiotic, DS-01®BOSTON, May 20, 2024 /PRNewswire/ -- Seed Health will present new clinical data on its flagship innovation, DS-01® Daily Synbiotic, a 24-strain probiotic and prebiotic, at the upcoming 2024 Digestive Disease Week® (DDW) meeting. The presentations will highlight the results from two randomized, double-blind, placebo-controlled clinical trials: one assessing the recovery effects of DS-01® on individuals during and following antibiotic usage, and another evaluating DS-01® in patients with irritable bowel syndrome (IBS). The findings underscore Seed's mission to transform breakthrough microbiome science into clinically validated consumer health innovations."DS-01® was formulated to maximize genomic diversity and set an entirely new standard in probiotics," stated Zain Kassam, M.D., M.P.H, Chief Medical Officer at Seed Health. "Our latest clinical data expands DS-01®'s potential health impact, broadens its clinical use cases, and helps dispel the common perception in the medical community that all probiotics are created equal."Dirk Gevers, Ph.D., Chief Scientific Officer at Seed Health, added, "The findings presented at DDW highlight the rigorous biopharma approach we bring to everyday health. We evaluated digestive well-being by studying biopharmaceutical-type biomarkers, exploring possible mechanisms of action in IBS, and conducting deeper microbiome sequencing than typical probiotic trials following antibiotics."DDW Presentation Highlights"Effects of a multi-species synbiotic on microbiome resilience and gastrointestinal barrier function after antibiotics: A randomized, double-blind, placebo-controlled clinical trial."This clinical trial evaluated the effects of DS-01® on individuals during and after antibiotic usage. Key findings include: DS-01® significantly improved short-term (25% at Day 7) and long-term (49% by Day 91) gut barrier integrity during and following broad-spectrum antibiotics
When the startup Seed launched an app for freelancers, microbusinesses, and other SMBs, it shared a survey of small business owners that revealed that 32% aren't separating their personal and business banking.
Dr. Kassam will lead Seed Health's clinical research and medical affairs, driving thedevelopment and validation of the company's microbiome health innovations and enhancing practitioner engagementBOSTON, April 24, 2024 /PRNewswire/ -- Seed Health , a microbiome science company, today announced the appointment of Zain Kassam, M.D., M.P.H., as Chief Medical Officer. An award-winning physician-scientist, Dr. Kassam has played a pivotal role in the advancement of microbiome science for over a decade. His extensive body of work includes over 200 peer-reviewed publications and abstracts, including in The New England Journal of Medicine, Nature Biotechnology, and Gastroenterology, and co-authoring international clinical practice guidelines. He has championed more than 30 Phase I-III clinical trials with top-tier academic institutions across multiple therapeutic areas
The initiative focuses on the discovery and application of microbes to enhance carbon sequestration, protect and restore vital ecosystems, and transform CO 2 into sustainable products.LOS ANGELES, April 22, 2024 /PRNewswire/ -- Seed Health, a microbiome science company, together with The Two Frontiers Project (2FP), a non-profit research organization dedicated to studying life in extreme environments, today announced a new initiative leveraging microbes for novel solutions to the climate crisis. Supported by SeedLabs, Seed Health's environmental division, this collaboration will discover microorganisms that thrive in extreme, CO 2 -rich environments and use their unique biochemistry to enhance carbon sequestration, restore vital ecosystems, and transform CO 2 into sustainable products.Credit: Seed Health / John KowitzExtremophile Microbes for Next-Gen Carbon TechCO 2 is warming the planet at record levels—50% in less than 200 years due to human activities—destroying critical ecosystems and leading to an unprecedented increase in ocean acidification. CO 2 levels today are higher than at any point in human history. Last year, on a landmark expedition supported by SeedLabs, the 2FP team discovered a novel volcanic microbe exceptionally efficient at consuming CO 2 , unlocking new potential in carbon capture technology. This latest initiative builds on that discovery, mining extreme environments for beneficial microorganisms and exploring broader applications of these microbes to mitigate climate change impacts. Dr
The new platform, CODA, employs AI and ML to translate insights from the Human Phenotype Project into advancements for metabolic health, brain health, menopause, and longevityCODA bolsters Seed Health's end-to-end platform for microbiome science to advance breakthrough research from discovery to real-world impactBOSTON, April 11, 2024 /PRNewswire/ -- Seed Health today launched CODA, a computational biology platform for the discovery and development of next-generation precision probiotics and microbiome-directed interventions. The platform is powered by the Human Phenotype Project —the world's most comprehensive multi-omics data set, emerging from the lab of computational biologist Professor Eran Segal, Ph.D., at the Weizmann Institute of Science. CODA elucidates previously unknown connections between the microbiome and health to develop targeted, outcome-specific interventions. First programs include cardiometabolic health, brain health, menopause, and longevity.The CODA PlatformCODA's dataset integrates over three million phenotypic data points from more than 13,000 individuals across 40,000 cumulative subject years, combining microbiome analysis with genetic, immune, metabolomic, and proteomic data. This multidimensional approach captures the diversity of human health factors, including biological, environmental, and dietary influences, lifestyles, and medical histories, to clarify critical interactions between the microbiome and host health and reveal unique insights into the mechanisms underlying health and disease."Our CODA platform is tracking the health data of tens of thousands of individuals over decades, offering a comprehensive, multi-omics perspective," explained Raja Dhir, Co-Founder of Seed Health. "This allows us to uncover and address critical connections between the microbiome and health, enabling the creation of targeted interventions to improve outcomes across diverse populations."CODA enhances Seed Health's full-stack platform, bolstering the company's computational microbiome capabilities across various microbiomes of the body and strengthening Seed's capacity to propel microbiome science from discovery to real-world impact.The Next Frontier of Microbiome ScienceCODA's combinatorial dataset unlocks a new level of insight into the microbiome's complex interactions with key biological systems, including the gut-brain, gut-heart, gut-liver, gut-skin, and gut-eye axes
Rescripted has partnered with Seed to run through some of the best foods you can eat in order to support your own gut health.